PMGC unit NorthStrive Biosciences launches independent FACS study for EL-22 manufacturing comparability

PMGC Holdings Inc.

PMGC Holdings Inc.

ELAB

0.00
  • NorthStrive Biosciences, a PMGC Holdings unit, plans an independent flow cytometry (FACS) study to quantify EL-22 latent myostatin antigen expression.
  • Program targets manufacturing comparability between NorthStrive-produced engineered Lactobacillus casei and prior EL-22 material made by MOA Life Plus.
  • Work aims to strengthen EL-22 product identity and manufacturing consistency, supporting IND-enabling development for the engineered probiotic candidate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100730PRIMZONEFULLFEED9760166) on July 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.